Lupin starts work on a new plant in India; FDA warning letters focus on contamination;

> Lupin, which already operates 11 manufacturing plants in India and Japan, has started construction of a new formulation facility in Mihan, Nagpur, India, which it expects to complete next year. Story

> Dalton Pharma Services in Canada has a contract to manufacture an antiviral agent developed by Defense Research and Development Canada (DRDC), for clinical trials in anticipation of getting the commercial contract later. Item

> An analysis by in-PharmaTechnologist of 2011 FDA warning letters found that a third of agency observations concerned the failure to have written procedures to prevent microbiological contamination. Report

> CRO Reaction Biology Corporation (RBC) has increased its epigenetic production capacity with a new facility in Malvern, PA. Article

> Industrial enzyme developer Codexis has gotten FDA approval for a new production process for manufacturing sitagliptin, the API in Merck's ($MRK) Januvia. More

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.